ANIKA THERAPEUTICS INC
ANIKNASDAQTrading Snapshot
- Day Range
- $19.77 – $20.21
- 52-Week Range
- $8.67 – $22.88
- Volume
- $3.28B
- Avg Volume
- $3.09B
- Shares Outstanding
- 13.4M
- Next Earnings
- Nov 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $113M
- Last Q Revenue
- $33M
- P/E Ratio
- -74.0
- P/S Ratio
- 2.2x
- EPS (TTM)
- $-0.28
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −0.4%
Why Investors Own ANIK
- ✓High-growth profile — revenue up +22.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 30% gross margin and 10% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ANIKA THERAPEUTICS INC
ANIK
StockOtter · stockotter.spaceAbout ANIKA THERAPEUTICS INC
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
ANIKA THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift ANIK price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
ANIKA THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.